New Treatment Modalities; Recombinant Factor VIII Products – “Factor VIII after 2008” (More Choices) Gita V. Massey, MD June 20, 2009.

Slides:



Advertisements
Similar presentations
Development of a Panel for Dengue Virus Maria Rios, PhD CBER/FDA Blood Products Advisory Committee Meeting December 14, 2010.
Advertisements

In the name of God. Summer School Influenza Unit, Pasteur Institute of Iran summer 2012.
Prevalence of HBV* by Region
WFH Bangkok 2004 Octanine F – Factor IX at its Peak Very High Purity Factor IX Virus Inactivation and Elimination Haemophilia B Treatment and Prophylaxis.
WFH Bangkok 2004 Octanate – Factor VIII with the Safety Factor VWF High Purity Plasma-Derived Factor VIII Double Virus Inactivated Haemophilia A Treatment.
LOGO In the Name of GOD. LOGO مصرف پلاکت و فرآورده های پلاسمائی شیراز خرداد 1393 دکتر آزیتا آذرکیوان متخصص کودکان؛ فوق تخصص هماتولوژی انکولوژی.
Treatment Products in Hemophilia
Hello. Blood Transfusion What is a Blood Transfusion? Blood transfusion is a medical procedure that needs to be ordered by a physician. It is the introduction.
Initiation substances activate s by proteolysis a cascade of circulating precursor proteins which leads to the generation of thrombin which in turn converts.
Is Nucleic Acid Testing for Organ Donors the ‘Right’ Choice? Reference: Humara A, Morrisb M, Blumbergc R, et al. Nucleic acid testing (NAT) of organ donors:
Chapter 12-Vaccines Traditional vs. rDNA vaccines Subunit vaccines Peptide vaccines Genetic immunization: DNA vaccines Attenuated vaccines Vector vaccines.
Octaplex – The Modern PCC
1 Douglas C. Lee, PhD Plasma Protein Therapeutics Association BPAC April 2011 Plasma Protein Therapies.
Emerging Trends in Plasma-free Manufacturing of Recombinant Protein Therapeutics Expressed in Mammalian Cells Yiben Wang 11/16/11 Leopold Grillberger,
Overview of Protein Therapeutics 1. Contents Introduction 1 Production 2 Delivery 33 Future Direction 44.
F. Kourgia, M. Vini, E. Zervou
Biopharmaceutical Products Touqeer Ahmed Ph.D. Atta-ur-Rahman School of Applied Bioscience, National University of Sciences and Technology 23 rd September,
Monoclonal antibodies Hybridoma Technique. Monoclonal antibodies (mAb or moAb) Monoclonal antibodies are:  monospecific antibodies that are identical.
Transfusion of Blood Product History: 1920:Sodium citrate anticoagulant(10 days storage) 1958: Plastic bag of transfusion 1656: Initial theory and.
Immunohematology (Blood Bank) CLS 245. What is Immunohematology? It is the study of Antigen-Antibody reaction as they relate to blood disorder.
Hemophilia A By Marissa Miuccio.
Vaccines Polio - close to eradication. In 2001 >1000 cases worldwide; last wild case in Americas in Peru in 1991.
General Approach of Haemostasis
BioLife Plasma Services Experience with HBV NAT Testing
Hemophilia Improving quality of life …until a cure…through L ower mortality I mproved outcomes F ewer hospitalizations E ducated independent patients.
Novel strategies for prevention and treatment of HIV infection Prasit Faipenkhong Pairoaj Vonghathaipaisarn Rodjana Chunhabundit Zhang Jianjun.
Food and Drug Administration Center for Biologics Evaluation and Research The Office of Cellular, Tissue, and Gene Therapies Web Seminar Series presents:
The HCV vaccine: cooperation in the shadow of the pyramids Antonella Folgori.
MIXING STUDIES General Approach of Haemostasis
Pharmaceutical Biotechnology PHT 426
Evaluation of Viral Clearance Studies
21th VHPB meeting on “Prevention of viral hepatitis in Italy: lessons learnt and the way forward” Catania, 7-8 november 2002 RESIDUAL RISK OF TRANSFUSION-
DIAGNOSIS OF HIV INFECTION THE LABORATORY BY DR. K.BUJJIBABU.MD.
BLOOD TRANSFUSION NUR 317. TRANSFUSION Infusion of blood products for the purpose of restoring circulating volume.
Division of Hematology Basil Golding M.D. Division Director Site Visits 2010 Laboratories of Hemostasis, and Plasma Derivatives.
Edible Vaccines. HOW IS IT DONE Approach 1 DNA sequences encoding antibodies (molecule which is able to recognise a disease-causing agent) are inserted.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 54 Drugs for Hemophilia.
Role of Factor Concentrates in Perioperative Coagulopathies Dr Neville Gibbs Department of Anaesthesia Sir Charles Gairdner Hospital.
Branches of Microbiology Bacteriology Virology Mycology Parasitology Immunology Recombinant DNA technology.
CHALLENGES FACED IN THE DEVELOPMENT OF BIOSIMILARS Dr.G.Hima Bindu MD; PG dip. diabetology Asst.Professor Dept. of Pharmacology Rajiv Gandhi Institute.
Lesson starter Once a protein has denatured, it cannot return to its original shape. Explain why. Haemoglobin is a protein found in the blood. Name two.
WAPPS project (web accessible pharmacokinetics service)
Preparation of blood components
ACTIVE AND PASSIVE IMMUNIZATION. Two types of immunization Active immunization - natural infection - vaccination, that provides people with an immunological.
professor in microbiology
Hepatitis Virus. Primary members HAV HBV HCV HDV HEV.
Evaluation of Viral Clearance Studies Mahmood Farshid, Ph.D. Div. Of Hematology OBRR/ CBER/FDA.
General principles for preventing high INR Simple dental or dermatological procedures may not require interruption to warfarin therapy. Simple dental.
Hemophilia Management: Joint Bleeds and Prophylaxis.
February 24, 2016 | 1 Paul Strengers MD, FFPM Sanquin Blood Supply Amsterdam The Netherlands Risk assessment schemes: Impact of.
Hepatitis B Fahad Alanazi.
PHYSICAL AND CHEMICAL INFLUENCES ON VIRAL INFECTIVITY
Vaccination Info. Journal of immunology Vaccination of HCWs was associated with reductions in total patient mortality from 17% to 10% (odds ratio [OR],
Blood Transfusion Products. Learning Objectives  To identify the products that can be derived from whole blood donations  To describe the conditions.
Plasma fractionation and viral inactivation/removal procedures
Viral vaccines  .
Recombinant Hormones and Drugs.  Many human disorders traced to absence or malfunction of a protein normally synthesized in the body  eg. Sickle cell.
Vaccine; To be effective  Must stimulate as many of the body's defence mechanisms as possible.  It is not necessary to get 100% uptake of vaccine in.
Prothrombin complex concentrate
In The Name of God.
Hepatitis B immune globulin
Edible Vaccines.
Recent advances- Novoseven
General Approach of Haemostasis
Northeast Biomanufacturing Center and Collaborative
Protein average weight : Half life: 14.7 ± 10.4 hrs
General Approach in Investigation of Hemostasis
פקטורי קרישה- כל מה שרציתם לדעת (כמעט) ולשאול
Hemophilia By: Renee Marie Alta.
IVIg Therapy. IVIg Therapy What are Immunoglobulins? Immunoglobulins, also known as antibodies, are proteins that bind specifically to antigens Immunoglobulin.
Presentation transcript:

New Treatment Modalities; Recombinant Factor VIII Products – “Factor VIII after 2008” (More Choices) Gita V. Massey, MD June 20, 2009

The Goals of Safe Therapy Promote adequate hemostasis with minimal side effects Promote adequate hemostasis with minimal side effects Prevent transmission of viral and “other” pathogens Prevent transmission of viral and “other” pathogens Decrease thrombogenicity of concentrates used to treat Factor IX deficiency Decrease thrombogenicity of concentrates used to treat Factor IX deficiency Promote hemostasis in the presence of inhibitors (and minimize inhibitor formation?) Promote hemostasis in the presence of inhibitors (and minimize inhibitor formation?) Cost and ease of use Cost and ease of use

Safety from Pathogen Transmission Donor selection Donor selection Plasma screening Plasma screening Viral inactivation Viral inactivation Recombinant products Recombinant products

Where are we coming from? Donor Selection Recovered plasma from volunteer donors Recovered plasma from volunteer donors Questioning about infectious risks Questioning about infectious risks Source plasma from apheresis donors Source plasma from apheresis donors

Where are we coming from? Plasma Screening 1940’s – syphilis 1940’s – syphilis 1972 – hepatitis B surface antigen 1972 – hepatitis B surface antigen 1985 – HIV antibody 1985 – HIV antibody 1987 – ALT (surrogate marker for hepatitis) 1987 – ALT (surrogate marker for hepatitis) 1990 – Hepatitis C antibody 1990 – Hepatitis C antibody Now – “NAT” (nucleic acid testing) HAV, HBV, HCV, HIV, B-19 Now – “NAT” (nucleic acid testing) HAV, HBV, HCV, HIV, B-19

Where are we coming from? Viral Inactivation Heat treatment Heat treatment Late 1970’s, early 1980’s -“pasteurization” and “dry” Late 1970’s, early 1980’s -“pasteurization” and “dry” Not effective for hepatitis, B-19 Not effective for hepatitis, B-19 Fear of increased inhibitors with denatured protein Fear of increased inhibitors with denatured protein Solvent Detergent Solvent Detergent Dissolving lipid envelopes of viruses Dissolving lipid envelopes of viruses Not effective against HAV and B-19 Not effective against HAV and B-19 Increased Purification Increased Purification Specific activity (increase amount of desired protein) Specific activity (increase amount of desired protein) 1980’s – immuno-affinity purification (monoclonal antibodies) 1980’s – immuno-affinity purification (monoclonal antibodies) High purity does not equal high safety High purity does not equal high safety

REMEMBER CDC maintains surveillance over viral infections transmitted by plasma products CDC maintains surveillance over viral infections transmitted by plasma products Last HIV transmissions from a USA concentrate were in 1987 Last HIV transmissions from a USA concentrate were in 1987 No viral-inactivated concentrate made from HIV-Ab screened plasma has transmitted HIV No viral-inactivated concentrate made from HIV-Ab screened plasma has transmitted HIV No transmission of hepatitis by modern concentrates has been observed No transmission of hepatitis by modern concentrates has been observed

We have arrived! The Recombinant Products 1990’s 1990’s Human genes transfected into nuclei of hamster cells Human genes transfected into nuclei of hamster cells Cells replicate and express factor in culture medium Cells replicate and express factor in culture medium Factor is extracted from culture medium by chromatography Factor is extracted from culture medium by chromatography Factor stabilized – albumin or sugars Factor stabilized – albumin or sugars

Recombinant Products Advantages Advantages Less viral contamination Less viral contamination Production of “designer” molecules Production of “designer” molecules Disadvantages Disadvantages Discordance of labelled units (in vitro) vs. recovery in patients (in vivo) Laboratory assay methods Cannot absolutely exclude pathogenic viruses in hamster cell cultures

The Product Generations First Generation First Generation Media enriched with human or animal plasma proteins for initial cell culture Albumin in final formulation Second Generation Second Generation Sucrose substituted for albumin in final formulation Third Generation Third Generation No human or animal plasma proteins in purification or final formulation

The Products Recombinate (Baxter – 1 st generation) Recombinate (Baxter – 1 st generation) HelixateFS/KogenateFS (Bayer/ZLB Behring – 2 nd generation) HelixateFS/KogenateFS (Bayer/ZLB Behring – 2 nd generation) ReFacto (Wyeth – 2 nd generation) * ReFacto (Wyeth – 2 nd generation) * Advate (Baxter – 3 rd generation) Advate (Baxter – 3 rd generation) Xyntha (Wyeth – 3 rd generation) Xyntha (Wyeth – 3 rd generation) *ReFacto will not be available after 5/31/09

Production of Factors RECOMBINA TE KOGENATE FS HELIXATE FS REFACTO (*ReFacto will not be available after 5/31/09) ADVATEXYNTHA CELL LINE FOR EXPRESSION CHOBHKCHOCHOCHO FVIII MOLECULE Full- length B-domain deleted Full- length B-domain deleted STABILIZERHumanalbuminSucroseSucroseTrehaloseMannitolSucrose Polysorba te 80 PLASMA ALBUMIN- FREE METHODNoNoNoYesYes VIRUS INACTIVATIO N/ PURIFICATIO N IA, IE IA, IE, SD ultrafiltrat ion IA, IE, SD nanofiltra tion IA, IE, SD ultrafiltrat ion IA, IE, SD nanofiltra tion

Clinical Efficacy of Factors RECOMBINATE KOGENATE FS HELIXATE FS REFACTO (*ReFacto will not be available after 5/31/09) ADVATEXYNTHA STUDIES PUP and PTP PTP PUP in prgress EFFICACY 92-95% Excellent/ good80-90%Excellent/good 100% surgery 92%Excellent/good86%Excellent/good 92.5%Excellent/good HALF-LIFE 14.6+/- 4.9hrs 13.3+/- 1.6hrs 14.5+/- 5.3hrs 12.0+/- 4.3hrs 11.5+/- 5.2 hrs INHIBITORS 32% in PUP 16% in PUP 30% in PUP 16% in PUP PUP in prgress

Ease of Use of Factors RECOMBINATE KOGENATE FS HELIXATE FS REFACTO (*ReFacto will not be available after 5/31/09) ADVATEXYNTHA VIAL RANGES 250, 500, 1000IU 250, 500, 1000, 2000IU 250, 500, 1000, 1500, 2000IU 250, 500, 1000, 1500, 2000, 3000IU 250, 500, 1000, 2000IU FINAL VOLUME 10ml2.5ml4ml5ml 4ml 4ml STORAGE Refrigerate or room temp Refrigerate or room temperature for 3 months Refrigerate or room temp OTHER “PERKS” Peel-off label Color-coded Color-coded Butterfly needle Color-coded Peel-off label Color-coded Butterfly needle Color-coded

The Issue of Cost Cost of Factor to Family Cost of Factor to Family Co-pays directed by insurance Co-pays directed by insurance Insurance formularies Insurance formularies Insurance caps Insurance caps Cost of Factor to Insurance Company Cost of Factor to Insurance Company Average wholesale price of medication Average wholesale price of medication Contractual agreements Contractual agreements

Evidence Based Use of Recombinant Factors Strong Evidence Strong Evidence rVIIa rVIIa Inhibitors Inhibitors Allergic reactions to IX Allergic reactions to IX Purified IX Purified IX Patients with increased thrombotic risk Patients with increased thrombotic risk “Subjective” Evidence “Subjective” Evidence Consumer perception of risk is serious and valid Newly-diagnosed patients and patients who have only used recombinant factors in the past

The Other Recombinant Factors Benefix Benefix Factor IX deficiency Factor IX deficiency Similar production to factor VIII products Similar production to factor VIII products Problems with calculated dose matching recovered dose Problems with calculated dose matching recovered dose NovoSevenRT NovoSevenRT Used for Factor VII deficiency, platelet disorders, inhibitors Similar production to factor VIII products Problems include cost, very short half-life, antibodies, and possible thrombogenicity

The Global Picture 80% of estimated 400,000 people with hemophilia receive no treatment 80% of estimated 400,000 people with hemophilia receive no treatment

The Future – Where are we Going? Gene Therapy Gene Therapy Coagulation factors bioengineered for improved therapeutics – the “designer molecules” Coagulation factors bioengineered for improved therapeutics – the “designer molecules” Improve biosynthesis and secretion Improve biosynthesis and secretion Prolong half-life – Pegylated liposomal products Prolong half-life – Pegylated liposomal products Decrease immunogenicity Decrease immunogenicity